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Umbilicalcordbloodhasservedasanalternativetobonemarrowforhematopoietictransplantationsincethelate1980s.Numerous
clinical studies have proven the eﬃcacy of umbilical cord blood. Moreover, the possible immaturity of cells in umbilical cord
blood gives more options to recipients with HLA mismatch and allows for the use of umbilical cord blood from unrelated
donors. However, morbidity and mortality rates associated with hematopoietic malignancies still remain relatively high, even
after cord blood transplantation. Infections and relapse are the major causes of death after cord blood transplantation in patients
with hematopoietic diseases. Recently, new strategies have been introduced to improve these major problems. Establishing better
protocols for simple isolation of primitive cells and ex vivo expansion will also be very important. In this short review, we discuss




Bone marrow (BM) has been used for years to treat hem-
atopoietic disorders such as leukemia. Indeed, the ﬁrst BM
infusion was performed in 1957 [1]. Although multiple
clinical studies with large numbers of patients have greatly
advanced ourknowledgeofBM transplantation (e.g.,[2–4]),
this approach still faces three major obstacles. (1) Finding
the desired donor, such as a human leukocyte antigen-
(HLA-) identical sibling, is often diﬃcult. A closely HLA-
matched, unrelated donor is an alternative option, though
the mortality associated with this type of transplant is high.
(2) Graft-versus-host disease (GVHD) occurs in recipients
at high frequencies, in some cases reaching 80–90% [3].
Transplantation ofBMfrom anunrelateddonoris anoption.
However, this is risky, and the mortality rate (estimated as
30–50% [4]) is higher than that seen in HLA-matched cases.
For the treatment of hematopoietic malignancy, autografts
are not available.(3)Isolation ofBM requiresinvasive proce-
dures, and mortality from infection can be as high as 50%.
BM is not the sole source of hematopoietic cells for
transplantation. Since the late 1980s, researchers have inves-
tigated the feasibility of using umbilical cord blood (UCB)
transplantation as an alternative to BM transplantation. The
ﬁrst hematopoietic reconstruction using UCB was reported
in 1989 [5]. Transplantation of HLA-identicaldonor-derived
UCB successfully reconstituted a patient suﬀering from Fan-
coni’s anemia [5]. Subsequent studies showed that UCB or
placental blood (hereafter also referred to as “UCB,” because
it shares a similar origin as UCB) is a useful alternative
to BM [6–8]. Initially, UCB was mainly used in children.
However, in 2001, a large multicenter trial suggested that
UCB is still eﬀectivefor hematopoietic engraftment in adults
[9].AlthoughhematopoieticreconstructionwithUCBseems
to be more diﬃcult in adult patients due to age-related
complications [8, 10] and the dose of cells required, this2 Stem Cells International
trial showed that UCB from unrelated donors or HLA-
mismatched donors still reconstituted hematopoietic sys-
tems. This ﬁnding increased the popularity of using UCB
as a source of blood cells for transplantation. This review
will begin with a discussion of hematopoietic stem cells
(HSCs)/hematopoietic progenitor cells (HPCs). This will be
followed by a discussion of how transplants can be improved
through advances in cell culture/bioengineering. Large-scale
culture systems and further improvements in engraftment
will be particularly important forclinical applicationof UCB
transplantation.
2.DiscoveryandEnrichment ofHSCs/HPCs
The discovery that stem cells (SCs) are present in human
UCB was made by Meulen’s group in 1978 [11]. Similar
reportsbytheothergroupsfollowed[12,13].Meulen’sgroup
reported that the number of SCs noticeably decreased in 8-
to 10-day-old infants [11], a ﬁnding that was conﬁrmed by
another group shortly thereafter [14]. This suggested that
a dramatic reduction of HSCs occurs in UCB upon aging.
Thus, UCB cells should be processed and stored as early as
possible.
Multipotent cells from either BM or UCB can produce
several diﬀerent hematopoietic cell colonies when grown in
agar. Kirshner and Goldberg compared the cells produced
by three diﬀerent sources of stem/progenitor cells (BM,
peripheral blood, and UCB) for the ﬁrst time in 1980 [12]
and noted diﬀerences in the cells produced by UCB cells.
Two striking diﬀerences existed between BM- and UCB-
derived colonies: (1) UCB produced a lower percentage of
eosinophils (approximately 2-3 fold less) as well as (2) more
macrophage and granulocyte colonies [12]. Characterization
and comparison of stem/progenitor cells in BM and UCB
still continues, and completely new trends might appear.
However,thisearly study clearlypointed tomajor diﬀerences
between BM and UCB.
Weismann’s group was the ﬁrst to isolate and purify
mouse HSCs from BM [15]. By this time, studieshad already
suggested the presence of cells capable of repopulating all
hematopoietic lineages. Weismann’s group puriﬁed a Thy-
1lowLin−Sca-1+ fraction of HSCs. Later, Rhodamine 123-
based staining revealedthat Lin−Sca+ cellsare heterogeneous
[16],suggestingthattheinitialcriterionmaynotbesuﬃcient
to purify the most primitive HSCs. Because HSCs or
primitive HPCs constitute only a very small fraction of total
UCB,identifyingprimitiveHSCs/HPCsforexvivoexpansion
is very important. In the early 1990s, CD34 was already
known to be a useful cell surface antigen for enriching
HSCs (reviewed in [17]). Reams of studies have addressed
the use of additional markers, and some have uncovered
discrepancies suggesting that CD34+ may not be necessary
(see further discussion in later paragraphs of this section)
[18–20]. Nevertheless, CD34+CD38− is a widely accepted
criterion for enriching primitive HSCs/HPCs [21]. c-Kit
(stem cell factor receptor) [22, 23] and Thy-1/CD90 [24]
have also been proposed as cell surface markers of primitive
HPCs, though they are not well accepted. CD34+CD38−,
Lin−, and probably Sca+ m a yb er e a s o n a b l ec r i t e r i af o r
selecting a highly enriched, primitive fraction from UCB.
In a recent study, CD150−CD48−Lin− was used to enrich
HSCs from mouse peripheral blood cells [25]. New studies
may use better, more updated criteria for enriching the
HSC/HPC fraction from UCB cells; however, whether these
selection parameters are useful for identifying the most
primitive HSCs in human UCB or other sources is unclear.
Broxmeyer’s review provides a useful guide to the current
standard protocol for isolation of HSCs/HPCs from UCB
[26].
As already mentioned, controversy exists over whether
CD34expressionisreliableforselectionofHSCs.CD34− and
CD34+ cellsmaybeinterchangeablephenotypes(reviewedin
[27]). Discrepancies in cell surface expression of CD34 may
beexplainedbythehypothesisthatCD34ismainlyexpressed
in intracellular compartments at early stages. BM CD34−
cells were reported to generate CD34+ cells after transplan-
tation. This may be supported by the idea that CD34low/−
cells home toward BM, where the cells appear to gain cell
surface expression of CD34 [20]. Although several papers
describedpotentiallyprimitiveCD34− cells[18–20],whether
these cells express CD34 in intracellular compartments is
unknown [28]. The above uncertainty might preclude the
CD34+ phenotype from being used as the gold standard in
preparing primitive cells for clinical application.
In current HSC/HPC research, several antibodies are
combined to select primitive cells. This provides very useful
information for laboratory-level studies. However, as in
some examples discussed above, cells could acquire or lose
phenotypes during ex vivo culture. For this reason, other
methods may be more convenient in clinical settings. The
use of chemical or enzymatic activity-based selection would
be a great advantage if available and would minimize the
use of antibodies, lowering production costs. Interestingly,
HPCs have been shown to highly express cytosolic aldehyde
dehydrogenase (ALDH) [29]. Storms et al. successfully syn-
thesized a ﬂuorochrome- (BODIPY-) conjugated substrate
for ALDH, which produces ﬂuorescence upon enzymatic
cleavage by ALDH [30]. Using this novel tool, they were
able to perform a relatively simple, ﬂuorescent dye-based
selection of HPCs.
Exploring the best set of markers to isolate the cells har-
boring the best potential for transplantation is very impor-
tant. However, using a combination of several cell surface
antigens for the selection of HSCs/HPCs will considerably
reduce the number of cells in the ﬁnal fraction. Pursuing fur-
ther markers to obtain absolutely pure HSC/HPC fractions
may not be necessary. Simple, CD34-positive selection still
yieldscellswithenoughexpansion capacity[31].Inaddition,
it should be noted that “primitive” cells and “proliferative”
cells do not necessarily share the same characteristics, and
the most important goal may be to secure suﬃcient capacity
for expansion and in vivo engraftment.
3.Transplantation
3.1. Immaturity of UCB Cells. Because BM transplantation
has a longer history than UCB transplantation, fundamentalStem Cells International 3
questions remain about UCB transplantation. For example,
“what is special in UCB and what advantages does UCB
(HSCs/HPCs)have?” Clinicaltrials havebasicallyshown that
UCB transplantation causes less GVHD and graft failure
[6–9, 32, 33]. Recipients seem to be less sensitive to HLA-
mismatching when UCB is used as a source of HSCs/HPCs.
One clinically interesting fact is that UCB myeloid
progenitor cells are relatively chemoresistant [34]. This is
very important because blood cell transplantation is often
combined with intensive chemotherapies to reconstruct host
immune systems. Use of chemoresistant UCB cells with
more intensive chemotherapies may avoid the relapse of
diseases that are sometimes observed after the treatment of
hematopoietic malignancy.
If UCB cells have better potential than BM cells to
be engrafted into recipients, then what is the underlying
mechanism(s)? The immunological potential of T cells is
thought to be one of the key determinants of successful
long-term engraftment of transplanted HSCs. A study by
Harris et al., which was the ﬁrst to systematically measure
a signiﬁcant number of samples, showed that UCB cells were
unresponsive compared to peripheral blood cells, although
IL-2 stimulation could still induce NK cell-mediated lysis
of target cells [35]. A slightly lower level of T cell receptor
expression was also reported. The authors found that UCB
contained CD3− cells, which were not present in peripheral
blood [35]. In addition, although the percentage of B
cells was comparable between peripheral blood and UCB,
approximately50%ofBcellsinUCBwere CD5+,amarkerof
immature B cells [35]. This ﬁnding led the authorsto suggest
that UCB lymphocytes are functionally immature. UCB cells
are less likely to cause GVHD than BM or peripheral blood
cells. Interestingly, UCB also showed less cytotoxicity against
NK cell-resistant tumor cells. This ﬁnding requires careful
investigation, as less antitumor activity in reconstituted
hematopoietic cells could increase the risk of relapse of
hematopoietic malignancies. That is, functional immaturity
of UCB lymphocytes may be a “double-edged sword.”
UCB transplantation apparently yields better responses in
recipients, such as decreased GVHD; however, the long-term
clinical outcomes of using UCB may not be signiﬁcantly
better than those achieved with other blood sources.
Although T-cell depletion does not seem to be necessary
for UCB transplantation [36], subpopulations of patients
undergoing UCB transplantation still experience problems
such as GVHD and a relatively poor survival rate, possibly
d u et ot h eh i g h e rp e r c e n t a g eo fH S C so ri m m a t u r i t y
of hematopoietic cells in UCB [8, 10]. A small dose of
transplanted cells is also thought to be associated with graft
rejection. Progenitor cell content may be particularly impor-
tant for successful engraftment [37]. Potential solutions are
discussed in Section 4.
3.2. Animal Studies of UCB Engraftment and Repopulat-
ing Potential. A comparison of UCB, BM, and peripheral
blood cells has shown that UCB cells engraft better than
cells from the latter two origins when transplanted into
nonobese/severe combined immunodeﬁcient (NOD/SCID)
mice. In vitro and in vivo studies conducted by Kim et al.
revealed that UCB-derived CD34+ cells not only have better
colony-forming ability than BM-derived CD34+ cells, but
also show signiﬁcantly better engraftment in NOD/SCID
mice [38]. One very interesting ﬁnding of this study is
that the level of chimerism is better in mice transplanted
with total UCB cells than partially puriﬁed UCB cells
(CD34+ cell fraction) [38]. This ﬁnding implies that the
CD34− fraction may contain some cells that support the
engraftment of transplanted cells. If this ﬁnding is appli-
cable to humans, again, enrichment of cells based on cell
surface CD34 may not be necessary for transplantation.
Interestingly,UCBisthoughttocontainasigniﬁcantlyhigher
number of multipotent and CD34+CD38− cells than BM.
Hoﬀman’s group developed an in vivo competition assay
to analyze the BM repopulating potential of UCB cells.
They established mice implanted with human fetal bones
[39]. After irradiation, HLA-mismatched UCB or adult BM
cells were injected individually or in combination. UCB
and adult BM CD34+ cells showed similar multilineage
hematopoiesiswhen equalnumbers ofUCBorBMcellswere
injected individually. However, UCB outcompeted BM cells
in repopulating BM when both were simultaneously injected
[39]. This result suggests UCB HSCs/HPCs have superior
capacity to engraft and repopulate. Thus, studies in animal
model systems support the idea that UCB is superior source
of hematopoietic cells than BM.
4.Approachesto Improving UCB
TransplantationOutcomes
4.1. Engraftment. Aside from increasing the dose of cells,
accelerating thehoming ofHSCs/HPCstohematopoietictis-
sues could considerably improve engraftment. Although the
exact molecular mechanisms underlying HSC/HPC homing
remain unclear, a chemokine, stroma-derived factor-1α
(SDF-1α), has been shown to play an important role in BM
engraftment of HSCs [40]. In vitro experiments showed that
this factor induced chemotaxis of UCB progenitors as well as
BM cells [41]. In spite of this in vitro chemotactic activity,
clinical trials have shown that neutrophil recovery is slower
after UCB transplantation than after BM transplantation
[32, 36], a ﬁnding that might reﬂect slower migration of
UCBcellsthanBMcellstowardtheBMaftertransplantation.
The functional immaturity of UCB cells may make it more
diﬃcultforthese cellstorapidly hometothe correctlocation
(i.e., BM). This might explain why UCB transplantation
requiresalongertimetoshowbeneﬁcialeﬀects.Interestingly,
the cell surface dipeptidylpeptidase, CD26, is suggested to
negatively regulate in vivo homing and engraftment of HSCs
[42]. This protease can cleavethe N-terminal dipeptide from
several cytokines, including a chemokine SDF-1 (CXCL12)
[43].ThisproteolysisdampensthebiologicalactivityofSDF-
1i nc h e m o t a x i s[ 44]. Moreover, a recent study by the same
group demonstrated that the percentage of CD26+ cells is
higher in immature, primitive cells (CD34+CD38−)t h a ni n
mature cells [45]. These ﬁndings suggest that inhibition of
CD26 may be a promising strategy for improving clinical
outcomes. Enhancing HSC/HPC homing may reduce the
dose of cells required for transplantation.4 Stem Cells International
4.2. Infection and Relapse. Infection is the major compli-
cation following transplantation. In one study, all patients
experienced at least one infection after transplantation
[46]. One characteristic of UCB transplantation is the slow
neutrophil recovery that occurs relative to BM transplan-
tation [36]. Although increasing the dose of transfused
cells certainly shortens the neutrophil recovery time [8],
this may not be a realistic solution because of the low
availabilityofUCBcells.Unfortunately,treatmentofpatients
with granulocyte-colony stimulating factor or granulocyte
macrophage-colony stimulating factor is not eﬀective in
improving neutrophil recovery [32]. It is not yet clear
whether slower neutrophil recovery increases morbidity
and mortality by infection. Nevertheless, cotransplantation
of neutrophils or their precursors might improve clinical
outcomes. Indeed, in one study, such cotransplantation
accelerated neutrophil recovery and reduced bacterial and
fungal infections [47]. Because the number of neutrophils is
limited in blood samples, ex vivo expansion of neutrophils
is necessary. Few studies have tackled this topic. The most
recent, conducted by Timmins and colleagues, has yielded
very encouraging results with regard to clinical application
of neutrophil coinfusion. The authors successfully expanded
functional neutrophilsin a large-scale bioreactor at a volume
up to 10 L [48]. Expanded neutrophils showed respiratory
burst activity to generate reactive oxygen species and killed
the fungus, Candida albicans. The system that the authors
used is capable of processing culture volumes up to 500 L
[48].
Most recently, a new strategy has been introduced
to combat infections and leukemia relapse, major factors
causing death of transplant recipients. Michlethwaite and
colleagues have generated cytotoxic T lymphocytes (CTLs)
harboring both antiviral and antileukemic activities [49].
A retrovirus-coded single-chain anti-CD19 fragment was
introduced into T cells prepared from peripheral blood
and UCB. The resulting CTLs showed speciﬁc and strong
cytolyticactivity against B-cell acute lymphoblastic leukemia
as well as against cell lines, demonstrating its clinical
potential in combating leukemia relapse and viral infections
concomitantwithbloodtransplantation.Althoughtheintro-
duction of a retrovirus-encoded chimeric gene may bring
some concerns, this strategy is very straightforward, and
the outcome of the study suggests that this approach holds
promise in reducing infections and leukemia relapse-related
mortality in patients in the future.
5.Expansion
5.1. Culture Supplements Used for Expansion. The limited
number of HSCs/HPCs is the major obstacle in blood
transplantation. Until the number of transplantable cells can
be increased to amounts necessary for adult patients, the
application of UCB should be limited to pediatric patients.
Eﬃcient methods are needed to obtain a larger quantity
of primitive cells from UCB. For this reason, developing
simple and realistic protocols for industrial-scale expansion
of primitive cells in UCB is essential.
Usually, the use of animal products such as fetal bovine
serum is inevitable for the propagation of SCs. Since
the HSC ﬁeld is well established, a serum-free culture
system is available to expand HSCs/HPCs, though room
for improvement still exists. A combination of several
c y t o k i n e si st y p i c a l l yu s e df o rex vivo culture of HSCs/HPCs.
Although the exact combination diﬀers among laboratories,
it usually consists of several cytokines such as Flt3/Flk2
ligand [50, 51], stem cell factor (SCF) [52, 53], interleukin-
3( I L - 3 )[ 54–56], IL-6 [57], and thrombopoietin [58–60].
Among these cytokines, SCF probablyhas the longest history
as a supplement. Flt3/Flk2 ligand may be more eﬀective
than SCF [61]. Flt3 ligand knockout mice exhibit serious
problems in the early development of HPCs [62], suggesting
that including Flt3/Flk2 ligand in the media is essential.
Interestingly, gp130 signaling (through IL-6) was reported
to synergistically enhance the eﬀect of SCF [63]. The same
trend was also reported for Flt3 ligand [64]. Thus, gp130
signaling appears to be supportive. It should be noted that
IL-6 alone was not shown to be eﬀective [54, 63, 64].
The eﬀect of IL-3 may need to be carefully evaluated,
because the addition of IL-3 was reported to suppress the
number of colony-forming cells [65]. It also reduced the
reconstitutingactivityofHSCs[65].Othercytokines,suchas
IL-7 and IL-11, are also suggested to promote proliferation
of HSCs/HPCs. IL-7 is likely more eﬀective in promoting
T-cell expansion [66] .T h u s ,i tm i g h tn o tb es u i t a b l ef o r
expanding primitive HSC/HPC populations. An unbalanced
increase in T-cell populations in ex vivo culture may increase
the risk of graft rejection. IL-11 might not be essential, since
the absence of IL-11 did not result in a dramatic diﬀerence
a f t e r1 0w e e k so fc u l t u r e[ 67]. Although some suppliers
can oﬀer bulk recombinant cytokines in these days, the
use of cytokines still increases the cost of expansion. Using
a combination of several cytokines also makes it diﬃcult
to know the exact molecular mechanism facilitating the
expansion of HSCs/HPCs. Further evidence suggests that a
feeder layer-based coculture system may also be good for ex
vivoculture. For example, porcine microvascular endothelial
cells (PMVECs) have been reported to be eﬀective for ex
vivo expansion of UCB cells [68]. Among several studies
investigating diﬀerent types of feeder layer-based culture
systems, that by Rosler et al. showed that the PMVEC
coculturesystem was 5-fold and 241-fold more eﬀectivethan
a stroma-free culture system (supplemented with cytokines)
forexpansion ofCD34+ and CD34+CD38− cells, respectively
(Figure 2 in [39]). However, coculture systems are probably
not suitable for large-scale production of cells. New culture
methods or supplements should provide more advantages,
while remaining simple. Two recent lines of studies, dis-
cussed below, may bring important breakthroughs in the ex
vivoexpansion of HSCs/HPCs.
Notch signaling has been proposed as a target to pro-
mote eﬃcient expansion of HSCs. The human homolog of
Drosophila Notch was originally discovered as a gene highly
expressed in CD34+ hematopoietic cells [69]. Incubation
of immobilized Notch ligand dramatically increases (by
approximately 100-fold) the number of CD34+ cells and
enhances repopulating ability in NOD/SCID mice [70].Stem Cells International 5
Table 1: Summary of culture supplements used for expansion.
Supplements Advantages Disadvantages
Flt3/Flk2 ligand
Popularly used in numerous
studies; serum-free conditions
available
Expensive for large-scale culture; diﬃcult to
determine the molecular mechanisms of the
action; too many combinations,which are






No need to supply expensive
growth factors Complicated culture systems
Notch ligand Eﬀective; signalingpathway is
relatively clear
Immobilization required; could induce
apoptosis under certain conditions
Aryl hydrocarbon receptor
antagonists
Deﬁned chemicals, can reduce
the cost Very new, further studies needed
Although Notch signaling was shown to initiate lymphoid
diﬀerentiation and enhance self-renewal, a repopulation
assay using NOD/SCID mice clearly demonstrated that
Notch ligand-incubated cells have far greater ability to
reconstitute host marrow. Notch ligand-treated cells injected
into mice were also capable of thymic engraftment, which
is typically unsuccessful [70]. Recently, the same group has
provided encouraging data, including preliminary results
of a phase 1 trial showing that CD34+ UCB progenitors
expanded with Notch ligand engraft better than control cells
[71]. One of the important observations in this study is that
transplantation of Notch ligand-expanded cells substantially
shortens neutrophil recovery time [71], a feature thought
to predict successful engraftment. Because clinical trials are
ongoing, Notch ligand-mediated ex vivo expansion may alter
clinicalregimens soon. Onepotentialpitfall relates tothefact
thatthesuccessfulresultsofthisstudywereobtainedusingan
immobilized Delta1 fusion protein. It should be noted that
Delta1-mediated Notch activation can induce apoptosis of
cells under certain conditions (such as when there is a high
density of ligand) [72]. The development of a more eﬀective
Delta1 ligand with reduced cytotoxicity would be desirable
for Notch ligand-mediated large-scale expansion.
Biological compounds such as growth factors/cytokines
may not be the only compoundsthat canbe used to promote
expansion. A recent study has shown that a chemical com-
pound could also be used for this purpose [73]. Chemical
compounds would be superior to biological compounds
because of lower production costs and greater ease of quality
control. Microscope-based high-throughput screening has
identiﬁed aryl hydrocarbon receptor antagonists as potential
drug candidates for promoting ex vivo expansion of HSCs
[73].Currently,thesecompoundsrequireacytokinecocktail.
However,further developmentofthisﬁnding may eventually
lead to chemically deﬁned culture media for clinical-scale
production of HSCs. Table 1 shows currently available
supplements (including those for feeder cell-based cultures)
for exvivoexpansion ofHSCs/HPCsand shortly summarizes
the advantages and disadvantages of each.
5.2. Large-Scale Culture Systems. Conventional culture ﬂasks
and gas-permeable blood bags [31]a r et h em o s tw i d e l y
used systems for the expansion of hematopoietic cells. The
ﬁrst automated bioreactor culture system for BM HPCs
was described in 1993 [74]. This ﬁrst system used a
continuous perfusion device, which was connected to a
syringe pump to allow fresh cell culture medium to be
supplied. This system, with supplements, allowed for up to
a 30-fold expansion of granulocyte-macrophage progenitor
cells; however, it was less eﬀective for other progenitors [74].
Advantages/disadvantages and other factors (e.g., oxygen,
pH, shear stress) are well summarized in Nielsen’s review
[75]. Recently, a rotating wall vessel was used for ex vivo
expansion of UCB cells [76]. Although the total cell number
was increased by 435 times, the expansion of CD34+ cells





Aside from being used for the treatment of hematopoietic
malignancy, SC transplantation has been used to improve
recovery from injuries and to accelerate wound healing.
These transplantations have beenconductedwith mesenchy-
m a ls t e mc e l l s( M S C s ) .H o w e v e r ,t h eh e t e r o g e n e i t yo fU C B
cells (a mixed system of endothelial progenitors, MSCs,
and HSCs/HPCs) may be useful for the systemic treatment
of conditions such as traumatic injury. To our knowledge,
no solid evidence shows that cord blood HSCs/HPCs are
eﬃcacious in wound healing. Nevertheless, one case report
using CD34+ cord blood cells suggests that the application
of cord blood SCs is of clinical interest [77]. The authors
also showed that cord blood cells can be mixed with ﬁbrin
gels, which is a popular material to apply cells onto wounds
in clinical settings. Further studies will be necessary to see
if cord blood SCs are eﬀective for wound healing. Whether
nonmesenchymal cells in cord blood (i.e., HSCs/HPCs)
play a major role in improving wound healing is not
clear. A small fraction of MSCs present in cord blood may
predominantly participate in wound healing. At the very
least, UCB likely possesses good potential to repair vascular
networks [78]. Because cell culture systems (i.e., serum-free
culture) have been relatively well established to comply with6 Stem Cells International
FDA regulations, UCB cells are readily available for potential
use in the treatment of traumatic injuries and burn.
7.ConcludingRemarks
Although engraftment of UCB cells and clinical outcomes
after UCB transplantation are promising, several aspects
of this approach must still be improved. First, mortality
due to infection (mostly bacteria) is nearly 50%, and this
h a sy e tt ob ei m p r o v e dm u c hf o re i t h e rB Mo rU C B
transplantation. Second,UCBmight haveslightly higher risk
in termsof relapse of diseases (i.e., leukemia)in exchange for
alowerrisk inacuteGVHD.Somenew strategies (neutrophil
coinfusion [47] and genetically modiﬁed cytotoxic T cells
[49]) have been developedto challenge these life-threatening
events (infection and relapse) occurring after transplan-
tation. Moreover, recent studies have demonstrated very
promising, exciting data that may be applicable to clinical
settings in the near future. For example, Notch signaling
ligand [71] and aryl hydrocarbon receptor antagonists [73]
have appeared as new tools that can be used to establish
ab e t t e ra n ds i m p l e rex vivo cell culture (Table 1). These
supplements may change currently used cytokines or feeder
cell-based culture systems; however, replacement of cytokine
cocktails with these new tools will likely take a while.
On the other hand, large-scale culture systems probably
need further improvement. Progressive incorporation of
cutting-edge techniques in the bioengineering ﬁeld would
be helpful for developing superior culturing devices. Highly
eﬃcient large-scale culture hold promise in making UCB
an alternative to BM. With well-deﬁned ex vivo expansion
protocols, UCB is likely to “rock” the area of blood cell
transplantation.
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